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Abstract
Background—Antibody responses to HY antigens in male recipients are frequent after
transplantation of stem cells from female donors (Miklos et al., Blood 2005; 105: 2973; Miklos et
al., Blood 2004; 103: 353). However, evidence that this B-cell immunity is accompanied by T-cell
responses to the cognate antigens is scarce. Here, we examined T- and B-cell responses to DBY
antigen in a male patient who received hematopoietic stem cells from a human leukocyte antigen-
identical female sibling.
Materials and Methods—We used 93 overlapping peptides representing the entire DBY
protein to detect and characterize T-cell and antibody responses to DBY by enzyme-linked
immunosorbent spot (ELISPOT) and enzyme-linked immunosorbent assay.
Results—High frequency CD4+ T cells specific for a unique DBY peptide were detected in the
patient blood. We isolated the corresponding T-cell clone and characterized the recognized epitope
as an 18-mer peptide restricted by human leukocyte antigen-DRB1*0101. Upon stimulation, this
clone produced cytokines with no evidence of Th1 or Th2 polarization. Remarkably, this clone
also recognized the DBX homologue peptide and responded to female donor dendritic cells
stimulated with poly I/C or lipopolysaccharide, indicating that the peptide was endogenously
processed in these cells. High titer DBY-specific antibodies were also found in the patient serum
which, in contrast to the T-cell response, did not cross-react with DBX.
Conclusion—We show here the development of a coordinated B and T-cell response to DBY in
a recipient of sex mismatched allogeneic hematopoietic stem-cell transplantation. Our findings
support a role for CD4+ T cells in the development of humoral immunity to minor
histocompatibility antigens.
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Studies from our laboratory have shown that sex-linked minor histocompatibility antigens
(H-Y) elicit isotype switched antibody responses in approximately 50% of male recipients of
allogeneic hematopoietic stem-cell transplants (HSCT) from female donors (1, 2). H-Y
antigens constitute a distinct class of minor histocompatibility antigen (mHA) encoded by
ubiquitously expressed male-specific genes located in the nonrecombining region of the Y
chromosome (3). These genes are significantly disparate from their homologues located on
the X chromosome. At the amino acid level, Y and X gene products show between 91% and
99% identity (4–11). Upon transplantation into male patients, female donor T cells elicit a
strong immune response directed to H-Y mHAs. H-Y-specific antibodies are associated with
a higher incidence of chronic graft versus host disease (cGVHD) and lower risk of tumor
relapse, suggesting a role in both graft versus host (GVH) and graft versus leukemia (GVL)
effects (1). It is presumed that an important component of humoral immunity is directed
toward allogeneic targets such as H-Y antigens. In humans, the conditions leading to the
development of such allogeneic antibody responses are still largely unknown. B-cell class
switch recombination is presumed to require help from CD4+ T cells specific for the
cognate antigens. We report here the comprehensive characterization of a coordinated T-
and B-cell response to H-Y antigen DBY in a male recipient of human leukocyte antigen
(HLA)-identical female HSCT.
RESULTS
DBY mHA Elicits a Sustained T-cell Response After HSCT
Ninety-three overlapping peptides representing the entire amino acid sequence of DBY were
synthesized and distributed in 12 pools. Peripheral blood mononuclear cells (PBMC)
collected from a male patient 31 months after receiving allogeneic stem cells from a female
donor were assessed for reactivity to each peptide pool using an interferon (IFN)-γ enzyme-
linked immunosorbent spot (ELISPOT) assay. To avoid skewing the representation of
potential DBY-reactive cells, ELISPOT assays were performed using unmanipulated
PBMC, without previous in vitro sensitization or expansion. A high level of reactivity was
observed towards one DBY peptide pool (data not shown). Testing of individual peptides
included in this pool assigned the reactivity to a single peptide, DBY 427–444 (Fig. 1A).
The frequency of IFN-γ producing T cells specific to this DBY epitope was approximately
1.5 × 10−4.We cannot rule out that additional DBY reactive T-cell clones secreting other
cytokines than IFNγ were also present in the patient blood. The high frequency T-cell
reactivity against DBY 427–444 was observed in PBMC collected at various times after
HSCT. As shown in Figure 1(B), the T-cell response was sustained between 18 and 38
months after transplant.
The DBY-Specific CD4+ T-Cell Response Is Restricted by HLA-DRB1*0101
ELISPOT experiments using PBMC depleted of CD4+ or CD8+ T cells revealed that DBY
peptide–reactive cells were included in the CD4+ T-cell subset (data not shown). One
CD3+CD4+ T-cell clone (clone 42; Fig. 2A) displayed the highest reactivity to donor B
cells immortalized with Epstein-Barr virus (EBV-B) pulsed with DBY 427–444 and was
expanded in vitro for further studies. T-cell receptor (TCR) Vβ repertoire analysis performed
using RNA extracted from clone 42 cells demonstrated clonality and revealed the usage of
the TCRVB2 segment (data not shown). Flow cytometry analysis using monoclonal
antibodies (mAbs) specific to TCRVB2confirmed the clonality of clone 42 (Fig. 2B). The
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specificity of clone 42 for DBY peptide 427–444, but not overlapping peptides, was
determined by IFN-γ enzyme-linked immunosorbent assay (ELISA) using donor EBV-B
cells pulsed with different concentrations of peptides as target cells (Fig. 2C).
As shown in Figure 2(D), stimulation of clone 42 with EBV B cells pulsed with DBY 427–
444 was inhibited by anti-HLA-DR mAbs, but not by anti-HLA class I antibodies. These
results suggested that TCR recognition was restricted by HLA-DR. Likewise, clone 42
reactivity was inhibited by a blocking mAb specific for TCRVB2 but not by a control mAb
specific for the TCRVB3 variable region. To determine which HLA-DR allele was
recognized by clone 42, we used a series of third-party allogeneic EBV B cells expressing
one of the two HLA-DR alleles expressed by both patient and donor: HLA-DRB1*1101 and
HLA-DRB1*0101. As shown in Figure 2(E), cells expressing DRB1*0101 stimulated clone
42 when pulsed with the antigenic DBY peptide, whereas cells expressing DRB1*1101 were
not recognized. These experiments demonstrated that presentation of the DBY 427–444
peptide to clone 42 was restricted by HLA-DRB1*0101. Analysis of the DBY amino acid
sequence using the SYFPEITHI epitope prediction algorithm attributed the highest score and
first rank to the antigenic peptide starting in position 427 compared with all other peptides
(see Table, Supplemental Digital Content 1, http://links.lww.com/TP/A438). This analysis
further confirmed the high affinity of peptide DBY 427–444 for the HLA-DRB1*0101
groove.
Both DBX and DBY Peptides Are Recognized by Clone 42
We then tested whether clone 42 would also recognize the corresponding X-encoded
peptide, DBX 429–446, which differs from DBY 427–444 by three residues (Fig. 3A).
Despite these disparate amino acids, both X and Y peptides stimulated clone 42 at a similar
level when pulsed on donor EBV B cells (Fig. 3A).
T-Cell Clone 42 Recognizes Endogenously Processed DBX Antigen in Stimulated Female
Donor Dendritic Cells
We determined whether clone 42 could recognize endogenously processed DBX protein in
female donor dendritic cells (DCs). Clone 42 was tested for its capacity to react to the
female donor DCs either unstimulated or stimulated with lipopolysaccharide (LPS) or poly-
I/C. As shown in Figure 3(B), stimulated DCs were recognized by clone 42, indicating that
DBX peptide was processed and presented to the T-cell clone. The clone stimulation was
blocked by anti-HLA-DR mAb.
Clone 42 Produces Both Th1 and Th2-Type Cytokines
Upon stimulation with peptide DBY 427–444, clone 42 produced a wide range of cytokines
(Fig. 4), including the pro-inflammatory Th1-type cytokines interleukin (IL)-8, IFN-γ, and
tumor necrosis factor α. Anti-inflammatory cytokines (Th2) IL-4, IL-13, and IL-10 were
also produced. Clone 42 did not appear to secrete IL-17, TGF-α, or IFN-α.
Development of an Antibody Response Specific to DBY
We investigated whether an antibody response to DBY and DBX antigens had also
developed after allogeneic transplantation in this patient. As shown in Figure 5(A), patient
serum collected 24 months after HSCT strongly reacted with recombinant DBY protein by
Western Blot assays. In contrast to the T-cell response, which did not differentiate between
DBX and DBY epitopes, DBY antibodies did not react with DBX. We then used 93
synthetic overlapping DBY peptides in ELISA assays to map the patient’s antibody response
and identify the corresponding antigenic epitopes. As illustrated in Figure 5(B), the serum
reacted with three peptides: DBY 7–25, DBY 104–122, and DBY 112–138. Even though
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antibody binding to peptides may not fully reflect binding to the native protein, it is
remarkable that the three peptide epitopes are located in regions of the protein that are the
most disparate between DBY and DBX.
We then used ELISA to assess the reactivity of serial serum samples collected at various
times after HSCT to the three most antigenic DBY peptides and their DBX counterparts.
Results reported in Figure 5(C) reveal the development of antibodies reactive to the DBY
peptides but not to the corresponding DBX peptides. The serologic response developed at 8
to 14 months after transplantation and reached a plateau between 14 and 27 months
posttransplant. Reactivity to these peptides started to decrease after 27 months posttransplant
and became virtually undetectable at 5 years postbone marrow transplantation. No reactivity
was detected before or 6 months after transplant, indicating that the antibody response
developed relatively late after HSCT.
DISCUSSION
Previous studies from our laboratory have shown that H-Y mHAs also elicit isotype
switched IgG antibody responses after allogeneic HSCT (2,12). We demonstrated that
approximately 50% of male patients who received HSCT from female donors developed
high titer antibody responses to DBY (2). The development of antibodies to H-Y correlated
with the development of cGVHD and disease remission, suggesting a role in both GVH and
GVL effects (1).
In addition, a number of clinical trials using rituximab have shown clinical improvement in
patients with steroid-refractory chronic graft-versus-host disease (for review [13]). One trial
performed at our institution resulted in clinical improvement in 70% of the patients, which
was associated with a decrease in anti-HY antibodies. These studies (review in [14])
highlighted the relevance of B-cell immunity after allogeneic HSCT. How these antibody
responses develop amid immune reconstitution in HSCT recipients remains obscure. Class
switch recombination, leading to the generation of antigen-specific IgG antibodies, is
presumed to require help from cognate antigen specific CD4+ T cells. To confirm this point,
we used a strategy aimed at detecting high frequency T-cell responses to DBY, a prototypic
H-Y antigen. As previously described, this approach consists in assessing the reactivity of
blood cells ex vivo to DBY without previous in vitro presensitization (12). In addition to the
high frequency T-cell response, the patients’ serum also revealed the presence of IgG
specific for DBY. Collectively, these observations support the hypothesis that antibodies to
H-Y develop with the help of cognate antigen-specific CD4+ T cells. Although DBY is not
expressed on the cell surface, this protein is expressed in many tissues. Anti-DBY antibodies
may enhance the uptake of this antigen by antigen presenting cell and its presentation to T
cells through the formation of immune complexes. These antibodies would thus participate
and exacerbate the immune response after tissue destruction.
Remarkably, CD4 T-cell clones reacted with both DBY and DBX epitopes, whereas
antibodies were specific for DBY and did not cross-react with DBX. These findings reveal a
complex autoimmune T-cell and alloimmune B-cell response, sharing a number of
characteristics with the anti-H-Y immune response that developed in another female to male
HSCT recipient (12). In the previous report, coordinated T- and B-cell responses were
described in a context of cGVHD, whereas in our present study these responses do not
appear to be associated with GVH. The two CD4+ T-cell responses were restricted by HLA-
DRB1*1501 and HLA-DRB1*0101, respectively. The sequences of the two recognized
DBY peptides show minimal homology. Both clones recognize DBY and DBX peptides and
both peptides are located in regions showing disparate amino acids between DBY and DBX.
DBY and DBX peptides differed by two amino acids in our previous report and by three
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amino acids in the current report. Further studies are needed to accurately define the
prevalence of such mHA-specific T cells after allogeneic HSCT and the extent to which T
cells with this pattern of reactivity contribute to both GVHD and GVL.
The presence of alloantibodies is associated with chronic GVHD and protection from
disease relapse after HSCT. Nevertheless, cases of transplant recipients with high antibody
titers to H-Y antigens without any manifestation of chronic GVHD have also been observed,
indicating that antibodies alone are not sufficient to induce damage to normal tissues after
HSCT. In the present study, the development of the antibody response and presence of T
cells specific to DBY coincided with interstitial pneumonitis, which was likely related to a
GVH reaction. Remarkably, high titer IgG and high frequency CD4+ T cells specific to
DBY persisted long after the clinical episode, at a time when the patient had no apparent
manifestations of GVHD. Even though the clinical incidence of anti-DBY antibodies can not
be determined from this work, our study suggests that anti-DBY antibodies may not
necessarily be detrimental but could also contribute to establishing long-term tolerance to
the recipient. Alloantibodies have previously been associated with tolerance after solid
organ transplantation or combined kidney-bone marrow transplant (15). Likewise, the sole
detection of CD4+ T cells specific for DBY in the blood may not be sufficient to appreciate
their role in vivo. Allospecific Tregs have also been described in mice and humans. In the
absence of chronic GVHD in this patient, it is tempting to speculate that DBY-specific T
cells may have had a regulatory function. A cytokine profile analysis of the DBY specific
clone did not reveal any clear pattern. Clone 42 secretes both Th1 and Th2 type cytokines
but did not produce IL-17.
Overall, our study provides additional evidence that H-Y mHA can elicit complex immune
responses combining isotype switched antibodies and specificCD4+ T cells in male
recipients of female HSCT. However, observing such immunity in the absence of GVHD,
suggests that H-Y specific immune cells and antibodies may not be pathogenic and may
even participate in tolerance mechanisms after HLA identical HSCT.
MATERIALS AND METHODS
Patient Characteristics
The patient studied in this report is a 63-year-old man with myelodysplastic syndrome who
received an allogeneic HSCT from his HLA identical sister. The patient received a reduced
intensity conditioning regimen before HSCT consisting of fludarabine and busulfan (16, 17).
The patient received cyclosporine and prednisone as prophylaxis for GVHD and
engraftment was achieved at day +7. The patient developed significant acute GVHD of the
gut 2 months after HSCT that was successfully treated with increased prednisone,
tacrolimus, and mycophenolate mofetil. At 16 months posttransplant, the patient developed
interstitial pneumonitis possibly related to chronic GVHD. No causative pathogen was
identified. He was successfully treated with prednisone for a period of 4 months when
symptoms resolved. The patient currently remains disease-free 10 years posttransplant
without clinical evidence of ongoing chronic GVHD and has a normal white blood count.
Peptides
Synthetic peptides were obtained from New England Peptides (Gardner, MA). Peptides were
crude (93 screening peptides; purity ~70%), or more than 85% purity (DBY420–437,
DBY427–444, DBY434–450, DBX201–218, DBX429–446, DBY7–25, DBX7–25,
DBY104–122, DBX104–123, DBY112–128, and DBX114–130). Each peptide was
reconstituted at 10 mg/mL in DMSO and stored at −20°C.
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ELISPOT assays were performed as previously described (18).
Cell Culture
T-cell clones were cultured in Roswell Park Memorial Institute (RPMI) 1640 supplemented
with 10% heat-inactivated human AB serum, glutamine, sodium pyruvate, Hepes, and
antibiotics (referred to as T-cell medium) in the presence of 100 U/mL recombinant IL-2.
Medium was replenished twice weekly with fresh IL-2. Immature DCs were obtained as
previously described (19). In brief, 40 to 60 × 106 PBMCs were incubated for 15 min in a 75
cm2 culture flask (Corning Inc.). Non-adherent cells were removed by thoroughly washing
the flask three times with medium. The remaining adherent cells were incubated for 1 week
in medium supplemented with 1000 U/mL IL-4 (R&D Systems) and 1000 U/mL
granulocyte macrophage colony-stimulating factor (GM-CSF) (R&D Systems). Cells were
then harvested, washed, and used as immature DCs. Maturation of DCs was achieved by
incubating cells for 24 hr with 25 ng/mL polyinosinic-polycytidylic acid (Amersham
Biosciences) or 100 ng/mL LPS (Sigma-Aldrich).
Generation of a DBY-Reactive T-Cell Clone
A T-cell line was first generated by stimulating 6 × 106 PBMC collected from the patient 31
months after HSCT in the presence of peptide DBY 427–444 at a final concentration of 25
µg/mL in the presence of 100 U/mL IL-2. One week after stimulation, CD4+ T cells were
immunopurified from the cell line using anti-CD4+ microbeads (Miltenyi Biotec, Auburn,
CA) and subsequently cloned by limiting dilution on feeder cells consisting of irradiated
patient EBV B cells (1.5 × 104 cells/well; 60 Gy) and allogeneic PBMC (7 × 104 cells/well;
35 Gy) in the presence of 100 U/mL recombinant human IL-2. All of the T-cell clones
generated were assessed for specific reactivity with the DBY peptide. Clone 42 displayed
the strongest reactivity and was further expanded under the same culture conditions with the
addition of anti-CD3 mAb (clone OKT3, eBioscience, San Diego CA) at a concentration of
30 ng/mL.
IFN-γ Secretion Assays
IFN-γ secretion by T-cell clone 42 was assessed by incubating 5 × 104 responder cells in 96-
well, U-bottom microplates with 5 × 104 stimulator cells in 200 µL T-cell medium
containing 50 U/mL IL-2. Stimulator cells consisted of autologous or third-party allogeneic
EBV B-cells pulsed with synthetic peptides (10 µg/mL or as otherwise stated) for 1 hr at
37°C and washed twice to remove excess peptide. Autologous cells were prepared from the
patient’ blood when hematopoietic chimerism was 100%. After 18 hr of incubation, 50 µL/
well supernatant was harvested and IFN-γ was measured using an ELISA kit (Pierce
Endogen, Rockford, IL) according to the manufacturer’s instructions. In experiments with
DCs, 10,000 immature DCs/well were incubated in 100 µL medium with or without LPS or
poly-I/C for 24 hr at 37°C. A total of 4 × 104 clone 42 cells were then added to the culture in
the presence of 50 U/mL IL-2, and secretion of IFN-γ was measured after 18 hr of
incubation.
Flow Cytometry
Clone 42 was labeled with an fluorescein isothiocyanate-conjugated anti-TRBV2 mAb
(clone MPB2D5, Beckman Coulter, Fullerton, CA), or a fluorescein isothiocyanate-
conjugated isotype control antibody (mouse IgG1, Beckman Coulter). Cells were analyzed
using a FC500 flow cytometer (Beckman Coulter).
Porcheray et al. Page 6













Clone 42 Cytokine Production Profiling
The T-cell clone 42 cytokine secretion pattern was determined by stimulating 5 × 104 cells
per well in 96 well U-bottom plate with 5 × 104 autologous EBV B-cells pulsed with DBY
peptide 427–444 or control peptide (DBX 201–218) at a concentration of 10 µg/mL for 24
hr. G-CSF, IL-2, IL-4, IL-6, IL-8, IL-9, IL-10, IL-13, IL-17, TGF-α, IFN-α, IFN-γ, and
tumor necrosis factor α were quantified in the culture supernatants using a custom multiplex
ELISA (Pierce SearchLight).
Epitope Prediction for HLA-DRB1*0101
Using the SYFPEITHI algorithm (http://www.syfpeithi.de/), we defined the “ligation
strength” of all 15-mer peptides throughout the DBY sequence to HLA-DRB1*0101. Each
peptide is given a score based on its affinity for the HLA molecule as calculated by the
algorithm. The table in Supplemental Digital Content 1 (http://links.lww.com/TP/A438)
displays ranking and starting positions of DBY peptides with the highest affinity for HLA-
DRB1*0101.
Recombinant Protein Production and Western Blot Assays
Recombinant DBX and DBY protein were produced and purified as described (2).
DBY ELISA Assays
Antibodies to DBX and DBY peptides were measured by ELISA as previously described
(2).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Sustained CD4+ T-cell response to DBY after allogeneic hematopoietic stem-cell
transplantation (HSCT). (A) ELISPOT assays for IFN-γ secretion were conducted using ex
vivo peripheral blood mononuclear cells(PBMC)collected 31 months after HSCT stimulated
with overlapping DBY peptides. (B) ELISPOT assays for IFN-γ secretion were carried out
using ex vivo PBMC collected serially between 18 and 38 months after HSCT stimulated
with DBY 427–444. Results are expressed as number of spots per 106 cells.
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The CD4+ T-cell response to DBY 427–444 is restricted by human leukocyte antigen
(HLA)-DRB1*0101 molecules. (A) CD4+ T-cell clones established from the patient blood
collected 31 months posttransplant were stimulated with donor Epstein-Barr virus (EBV) B-
cells pulsed with peptide DBY 427–444. IFN-γ secretion was measured after overnight
culture. Clone 42 displayed the high reactivity towards the antigenic peptide. (B) Flow
cytometry analysis of clone 42 stained with an anti-TRBV2 monoclonal antibody (white
histogram) or with an isotype control antibody (gray histogram). (C) The reactivity of clone
42 stimulated with increasing doses of peptide DBY 427–444 or 2 overlapping 18-mer DBY
peptides was measured by IFN-γ secretion. (D) CD4+ T-cell clone 42 stimulation with
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autologous EBV-immortalized B cells (autologous cells were prepared from the patient’
blood when hematopoietic chimerism was 100%) pulsed with DBY peptide 427–444 or a
control peptide (DBX 201–218) was assessed by measuring IFN-γ secretion in the culture
supernatant. On the target side, antigen recognition was blocked with anti-HLA-DR mAb
(G46.6, BD biosciences) but not anti-HLA class I mAb (W6/32, Sigma Aldrich). On the T-
cell side, antigen recognition was blocked with anti-TCRB2 mAb but not with anti-TCRB3
mAb. (E) Clone 42 was stimulated with a series of third-party allogeneic Epstein-Barr virus
(EBV)-B cells (LCL) sharing the expression of HLA-DRB1*0101 or HLA-DB1*1101 with
the patient after pulsing with DBY 427–444. IFN-γ secretion was measured in the culture
supernatant after overnight incubation.
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T-cell clone 42 recognizes both DBX and DBY antigens epitopes and DBX antigens
endogenously processed and presented by mature dendritic cells (DCs). (A) Clone 42 was
stimulated with autologous Epstein-Barr virus (EBV)-B cells pulsed with increasing
concentrations of DBY 427–444 peptide and its DBX homologue DBX 429–446. IFN-γ
secretion was measured in the culture supernatant after overnight incubation. Reactivity to a
control peptide, DBX 201–218, is also shown. Disparate residues between DBX and DBY
versions of the peptides are represented with underlined characters. (B) Patient’ (female)
DCs (104/well) were incubated for 24 hr with medium alone, poly-I/C, or lipopolysaccharide
(LPS) to induce maturation. T-cell clone 42 (104/well) was then added to the wells in the
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presence of IL-2 (50 U/mL). After 18 hr of incubation, secretion of IFN-γ was determined in
cocultures by ELISA. Same assay was run simultaneously in the presence of anti-human
leukocyte antigen (HLA)-DR mAb to block antigen presentation to the CD4 clone.
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Clone 42 cytokine secretion profile upon stimulation by DBY 427–444. Clone 42 was
stimulated with DBY 427–444 or a control peptide, DBX 201–218, pulsed on autologous
Epstein-Barr virus (EBV)-B cells. The secretion of different cytokines was measured in the
culture supernatant using a multiplex ELISA assay.
Porcheray et al. Page 14














Serologic IgG response to DBY but not DBX after hematopoietic stem-cell transplantation
(HSCT). (A). Recombinant DBY and DBX were expressed in human female 293 cells, and
total cell lysates were probed in Western blots with plasma collected at 24 months
posttransplant. Results with DBY and DBX are compared with 293 cells transfected with an
empty vector (mock transfectants). (B). A plasma sample collected from the patient 34
months after transplant was used to map the DBY-specific antibody response. The plasma
was diluted 1:50 and tested by ELISA for its reactivity to each of the 93 overlapping DBY
peptides (above x-axis). Reactivity to the DBY peptides was revealed with anti-IgG
secondary antibodies. The location of the T-cell epitope is indicated by an arrow. The
number of disparate amino acids between the DBY and peptides and their DBX counterparts
is also represented in this figure (below x-axis). (C). The patient plasma reactivity to the
three most immunogenic DBY peptides, 7–25, 104–122 and 112–128, and their DBX
homologues was assessed by ELISA using samples collected serially after allogeneic HSCT.
Disparate residues between DBX and DBY peptides are represented with underlined
characters.
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